SMALL CELL LUNG CANCER 1a LINEA DE MANTENIMIENTO
DÍA D MAÑANA EN #ESMO26
DELLPHI-305 ( TARLATAMAB+DURVALUMAB)
VERSUS IMFORTE
( LURBINECTEDIN+ATEZOLIZUMAB )
VEREMOS OS /PFS /HR
DIFERENCIAL: TARLATAMAB ENTRA EN CEREBRO
"IMFORTE NO"
https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer
#pharmamar @Amgen
118 views · 0 likes · 0 reposts · 0 replies
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Pharma Jonpi . / 1.1 / . · x.com